Lava Therapeutics B.V., a biotechnology company, develops proprietary Vγ9Vδ2 T-cell engagers. It develops immune oncology biopharmaceuticals that delivers treatment in combination with immune recruiting and activating functionality. The company was founded in 2016 and is based in Utrecht, the Netherlands.